Abstract 101P
Background
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Despite the availability of multiple treatment strategies, the prognosis of the patients with CRC is dismal. The aim of this study is to evaluate the efficacy and safety of cellular immunotherapy (CIT) (the use of autologous natural killer cells, γδTcells and cytokine-induced killer cells) in combination with chemotherapy in patients with CRC.
Methods
A retrospective analysis of 377 patients with colorectal adenocarcinoma from December 2010 to December 2015 was performed, including 97 patients in the CIT+chemotherapy group and 280 patients in the chemotherapy group. The primary endpoints were DFS or PFS (Patients with adjuvant therapy after radical resection of colorectal cancer had the same DFS as PFS). The secondary endpoints were OS, ORR, DCR, adverse reaction rate and treatment tolerance.
Results
The 3-year progression-free survival rate of CIT+chemotherapy group and chemotherapy group was 67.2% vs 53.9% (P < 0.01), and the 5-year OS rate was 74.1% vs 50.8% (P < 0.001). CIT+chemotherapy was independent prognostic factors for both DFS (HR: 0.618, 95% CI: 0.428–0.891) and OS (HR: 0.513, 95% CI: 0.335–0.784). The ORR and DCR of CRC patients with IV staging in the CIT+chemotherapy compared to chemotherapy group were 63.0% vs 50.8% (P = 0.291) and 81.5% vs 65.6% (P = 0.131) respectively. The percentage of CD3+, CD3+ CD4+ cell subsets were significantly increased from 70.11% to 75.87% (P < 0.01), and 42.53% to 44.39% (P = 0.02) in the CIT+chemotherapy group after treatment. Overall adverse reaction rate of CIT+chemotherapy group and chemotherapy group was 75.3% vs 75.4% (P = 0.98) respectively. In patients with stage III, the median chemotherapy course in CIT +chemotherapy compared to chemotherapy group is 8 vs 6 (P = 0.003).
Conclusions
High quality and standardized CIT combined with chemotherapy can promote the survival time, reduce the recurrence rate and improve the immune status of CRC patients. In addition, it is safe and low-toxic which improves the patient's tolerance to chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract